Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Biomarkers, Durvalumab Plus FLOT, and ctDNA in Gastroesophageal Cancer Care
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
3
Better Biomarkers Needed to Guide Neoadjuvant Chemoimmunotherapy in NSCLC
4
Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3
5